



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 25695

Title: Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?

Reviewer's code: 00503516

Reviewer's country: Italy

Science editor: Ze-Mao Gong

Date sent for review: 2016-03-22 16:18

Date reviewed: 2016-04-01 23:13

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Montella L et al make an update about the emerging anti HCC drugs focusing on those used in clinical trials phase II/III. The paper, well presented and clear, takes into account most of the novel drugs in the field. Minor comments In most cases, the authors describe, together with the therapeutic effects of the drugs, also the adverse effects. This is however not the case for the proteasome inhibitor bortezomib. Given the observed toxicity in vitro (see for example: Farra et al Biochimie 112 (2015) 85e95) it would be nice if the authors report and comment the adverse effects observed in patients compared to the in vitro toxicity.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 25695

Title: Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?

Reviewer's code: 02936403

Reviewer's country: Taiwan

Science editor: Ze-Mao Gong

Date sent for review: 2016-03-22 16:18

Date reviewed: 2016-04-01 23:53

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input checked="" type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

The manuscript by Montella et al., investigate whether novel targeted drugs really impact the next future. Overall, this manuscript is clearly written and discusses most of novel drugs in HCC therapy.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 25695

Title: Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?

Reviewer's code: 00680628

Reviewer's country: Taiwan

Science editor: Ze-Mao Gong

Date sent for review: 2016-03-22 16:18

Date reviewed: 2016-04-04 09:28

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input checked="" type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

MAJOR COMMENTS: The authors aimed to present an updated reviewed article about the emerging novel molecular targeting therapy against advanced HCC. However, most information were provided in descriptive form. For easy understanding, a table form may be clear and favorable (as Table 1 and Table 2 in the manuscript; including Child-Pugh grade, vascular involvement, tumor number and size, adverse effects, overall survival, etc.). HCC has been considered to be a relatively chemotherapy-refractory tumor due to the high expression of drug resistance genes. Besides tumor aggressiveness, degree of liver dysfunction and adverse effects of drugs may contribute to overall drug benefit. Systemic chemotherapy is usually not well tolerated by patients with significant underlying hepatic dysfunction. The authors should address these factors. Most HCC had underlying cirrhosis regardless of etiology. Most targeting therapy for advanced HC may have less efficacy in patients with significant cirrhosis. The manuscript provided many studies in ongoing clinical trials. As described in the discussion, "some of new molecules disappearing after phase I/II studies without published results". As this is a review article, drugs used in these clinical trials may be deleted because of unknown results. Targeting therapy in non-advanced HCC is worthy



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

mention. MINOR COMMENTS: 1. Reference 1 cited is inappropriate. It is published in 2008. Now is 2016. More reference about HCC epidemiology have been published during recent years. Please cited more appropriate articles.